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As the prevalence of both obesity and mental disorders continues to rise, 
researchers aim to determine the physiological mechanisms of these conditions.  Many 
people with obesity have medical comorbidities such as hypertension and 
cardiovascular disease, but there are often many psychological comorbidities to obesity 
as well.  The newly developing idea of the gut-brain axis has been theorized to play a 
role in linking many conditions via the gut microbiome, which exhibits distinct 
differences in obese and depressed individuals when compared to lean/healthy controls.  
Bariatric surgery, the frontier treatment method for sustained weight loss and improved 
metabolic functioning in morbidly obese patients, drastically changes the anatomy of 
the gastrointestinal tract along with the composition of the gut microbiome.  Depression 
is also associated with distinct changes to the gut microbiome.  The purpose of this 
review is to compare changes in the gut microbiome caused by bariatric surgery to the 
alterations of the gut microbiome in depressed individuals.  When obesity and 
depression co-occur following bariatric surgery, the role of the gut microbiome may be 
amplified, and further researching the mechanisms by which obesity, depression, and 
the gut microbiome interact will allow for more personalized treatments for both obesity 
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All systems that require a balance can be modeled using the concept of 
homeostasis, the use of feedback loops to maintain a set equilibrium point when a 
system changes in response to changing stimuli.  Overall physiological and 
psychological health is regulated by thousands of homeostatic feedback loops, and the 
disruption to any one of these loops can cause many pathways to sway from 
equilibrium.  Oftentimes in the treatment of clinical conditions, patients are asked to 
consciously alter the state of their psychological homeostasis to maintain or improve 
one’s physical and mental health.  As the prevalence of both obesity and depression 
continue to rise, researchers are looking into the imbalances that are associated with 
these conditions and how various treatments affect the reinstatement of patients’ 
homeostatic equilibrium.  Although it would be incorrect to point out a single reason as 
to why a person has obesity or depression, developing understanding of how all 
variables may cause or prevent against said conditions will make way for 
individualizing treatment and improving population health. 
There is an abundance of theories which attempt to explain how any condition 
comes to fruition.  One such theory which utilizes the basic concept of homeostasis has 
been presented by David Marks.  Marks proposes that health is maintained through four 
main categories:  physical health, life satisfaction (measured via subjective well-being), 
consumption (measured via restraint), and affect (positive or negative).  An imbalance 
in any of these categories will alter the outcoming affect.  Marks applies the 
relationships between these four attributes to obesity, introducing the idea that general 




the Circle of Discontent, a collection of feedback loops between these four main points 
in which any disequilibria are hard to control (Figure 1).   
 
Figure 1:  The Circle of Discontent 
The application of homeostatic health as a cause of obesity.  Imbalance of any one 
pathway connecting any two of the variables can induce poor homeostatic health.  
Disequilibrium of multiple pathways may result in a more severe affect.  Arrows 
connecting body dissatisfaction and energy-dense consumption are dashed due to 
inconsistent evidence (Marks, 2015). 
There are many ways this chart can be viewed.  For one, as weight gain changes 
physical health, food is overconsumed, body dissatisfaction increases, and the result is 
negative affect.  The cycle could also begin with other categories such as energy-dense 
consumption which causes weight gain, leading to body dissatisfaction and negative 




necessary for all factors to be out of alignment to result in negative affect.  Considering 
body positivity, body dissatisfaction may not play a large role for some individuals.  
This could possibly reduce the overall negative affect established by the remaining 
impact of overweight/obesity and energy dense consumption in Marks’ Circle of 
Discontent (Marks, 2015).  This theory describes obesity as a disruptive feedback loop 
that requires conscious intervention to return to equilibrium.  Marks considers a very 
broad view of the causes of health and disease.  Research is now narrowing the scope to 
understand how smaller internal systems impact the overall state of the host. 
Conforming to the idea of homeostasis, a person’s ideal body weight can be 
viewed as the set equilibrium weight.  This equilibrium, which seeks to maintain overall 
body composition at any weight, is carried out via many hormonal pathways that aim to 
physiologically control body weight via the control of food intake (Harris, 
1990).  Among these regulatory hormones are anorexigenic (appetite suppressing) 
glucagon-like peptide 1, cholecystokinin, leptin, and peptide YY along with orexigenic 
(appetite stimulating) ghrelin and pancreatic polypeptide.  A summary of body weight 
regulatory hormones and their physiological roles can be seen in Table 1.  These 
hormones often work by targeting either the vagus nerve, enteric nervous system, and/or 
the immune system to communicate with the central nervous system (Lean & Malkova, 
2016).  The hypothalamus works as a relay station for neural and hormonal signals from 
the body.  After processing, the hypothalamus propagates appropriate signals to bring 








Table 1:  Common Gut Hormones and their Corresponding Physiological Roles 
These hormones bring about the mentioned physiological affects upon secretion.  The hormones 
cause affect via homeostatic loops which aim to maintain a set equilibrium point for appetite, 
gastric motility, energy expenditure, etc. (Martin et al., 2019). 
Definition and Prevalence of Obesity and Depression 
According to the World Health Organization, obesity rates have nearly tripled 
since 1975.  Obesity is often defined using the Body Mass Index (BMI), calculated by 
dividing one’s weight (in kilograms) by the square of their height (in meters).  Those 
with a BMI of 25 or above are considered overweight and those with a BMI of 30 or 
above are considered obese.  BMI, while an indicator, is not a perfect tool to predict 
body composition and health risk.  Having an elevated BMI, like seen in many highly 
trained athletes, does not definitively mean someone is at risk for comorbid diseases 
associated with obesity such as type two diabetes, hypertension, non-alcoholic fatty 
liver disease, and cardiovascular disease to name a few (Apovian, 2016; Chooi et al., 
2019).  Discussing obesity is made complicated because the condition differs based on 
gender, race, ethnicity, sex, and age.  For example, men tend to accumulate more fat 
Hormone Physiological Role
Ghrelin Increase appetite, lipogenesis, glucose output from the liver, and gastric 
motility.
Pancreatic Polypeptide Increase appetite, lipogenesis, glucose output from the liver, and gastric 
motility.
Leptin Decrease appetite, energy balance.
Oxyntomodulin Decrease appetite, energy balance.
Cholecystokinin Decrease appetite, glucose output from the liver, and intestinal motility.
Glucagon-like Peptide 1 Decrease appetite, glucose output from the liver, and intestinal motility.
Peptide YY Decrease appetite, intestinal motility, and secretion of pancreatic enzymes.
Serotonin
Increase lipolysis, gastric motility, pancreatic enzyme secretion, and bile fluid 




within the abdominal cavity (i.e., visceral fat) than women which is more highly 
associated with risk for cardiovascular disease than subcutaneous fat (Tchernof & 
Després, 2013).  Obesity often results from complex relationships between genetic 
factors, socioeconomic status, and cultural influences.  Overall obesity prevalence is 
impacted by lifestyle habits, consumption patterns, and urban development (Apovian, 
2016).  
The World Health Organization identifies depression as a major contributor to 
global disease and disability that affects more than 264 million people worldwide.  
There are many types of depressive disorders that differ in severity but generalized 
moderate depression can be described as having a “sad, empty, or irritable mood, 
accompanied by somatic and cognitive changes that significantly affect the individual’s 
ability to function” (Diagnostic and Statistical Manual of Mental Disorders, 2013).  
People with depression often experience symptoms of dissatisfaction and loneliness that 
affect a person’s homeostatic category of subjective well-being.  Many studies have 
determined that obesity is a risk factor for depression and vice versa, although it may be 
impossible to determine if one causes the other.  A common component of both obesity 
and depression is loss of self-esteem, and it is theorized that this loss may often be a 
result of distorted body image in obese patients (Gutiérrez-Rojas et al., 2020).  Simon et 
al. (2008) interviewed thousands of middle-aged women.  The study showed that 
prevalence of depression increased from 6.5% in women with a BMI below 25 to 26% 
in women with a BMI above 35.  Further, they determined that obesity prevalence 
increased from 25% in women who did not claim to have depression to 58% in women 




obesity and depression and determining the mechanisms of this bi-directional 
relationship has become increasingly popular among researchers over the last decade.   
Treatments for Depression 
Depressive disorders are often treated using selective serotonin reuptake 
inhibitors (SSRIs), increase the amount of free serotonin available to bind to serotonin 
receptors (Harmer et al., 2017).  The neurotransmitter serotonin regulates behavioral 
and neuropsychological processes of mood, perception, reward, aggression, appetite, 
memory, sexuality, and attention (Berger et al., 2009).  Serotonin can carry out such an 
array of effects due to the complex system of peripheral and neural serotonergic 
neurons accompanied by approximately 14 subtypes of serotonin receptors located 
throughout the body.  The 14 receptor types are categorized into five families based on 
receptor structure, and each type is associated with its own physiological functions 
(Stahl, 1998).   
Central serotonin is produced primarily by the raphe nuclei, located in the 
midline of the brain stem.  Neuronal projections from the raphe nuclei innervate the rest 
of central nervous system to create the neuronal serotonergic system (Berger et al., 
2009).  The serotonin produced by the raphe nuclei is the population of serotonin 
capable of binding behavior-modulating serotonin receptor types located in the central 
nervous system.  The majority of the body’s serotonin is produced and released from 
enterochromaffin cells (also known as enteroendocrine cells) that line the digestive 
tract.  This population of serotonin can then travel throughout the body, binding to 
many subtypes of peripheral serotonin receptors to induce its effects (Mawe & 




of carbohydrates, short chain fatty acids (lipids), and bile acids (Martin et al., 2019).  
Peripheral serotonin has been found to regulate glucose homeostasis, lipolysis, bone 
density, and metabolic disorders such as Type 2 diabetes (Martin et al., 2017).  
However, peripheral serotonin does not easily cross the blood brain barrier, meaning 
peripheral serotonin cannot directly target mood regulating central serotonin receptors.  
Some studies have shown that supplementation with 5-Hydroxytryptophan, an 
intermediate of serotonin synthesis, may help increase central serotonin concentration.    
The rate limiting step of serotonin synthesis takes place when L-tryptophan is converted 
into 5-Hydroxytryptophan via the enzyme tryptophan hydroxylase.  By supplementing 
5-Hydroxytryptophan, this slow step is surpassed.  The blood brain barrier is permeable 
to 5-Hydroxytryptophan, meaning the molecule can supplement serotonin synthesis in 
the raphe nuclei after crossing, resulting in greater production of serotonin capable of 
modulating mood (Birdsall, 1998).  Supplementation of tryptophan, an essential amino 
acid as well as a precursor to serotonin, has also shown this same ability to cross the 
blood brain barrier where it can be synthesized into serotonin to induce positive 
behavioral outcomes (Steenbergen et al., 2016).  Although many see improved mood 
and social behavior with supplementation of tryptophan, tryptophan is also a precursor 
to other molecules such as melatonin which plays a role in regulating the sleep-wake 
cycle. This may impact efficacy of tryptophan supplementation on serotonin synthesis 





Bariatric Surgery as a Treatment for Obesity 
Aside from lifestyle changes to diet and physical activity levels recommended 
for losing weight, bariatric surgery has been shown to be the most effective for long-
term weight loss and metabolic improvement in morbidly obese patients (Buchwald et 
al., 2004).  There are many types of bariatric surgical procedures (Figure 2), the two 
most common being the sleeve gastrectomy (SG) and the Roux-en-Y gastric bypass 
(RYGB).   
 
Figure 2:  Anatomy of Bariatric Surgery Procedures 
Sleeve gastrectomy (A) and Roux-en-Y gastric bypass (B) (Ulker & Yildiran, 2019).  
In SG, approximately 70 percent of the stomach is removed with an incision, leaving 
behind a smaller pouch that resembles a banana.  This procedure does not affect the 
absorption of nutrients because it does not alter the anatomy of the intestines where 




from the rest to create a small pouch capable of holding only approximately 30 
milliliters in volume.  This pouch is then connected directly to the jejunum, so the 
bypassed remaining stomach and the duodenum attached to the small intestine create a 
Y-shape.  The bypassed stomach and duodenum continue to secrete gastric acid and 
hormones, but the patient’s nutrient absorption is greatly reduced because food no 
longer travels through the bypassed organs.  In general, these procedures work to limit 
the amount of food that can be consumed, leading to lesser caloric intake and weight 
loss which often allows for the betterment of comorbidities while also affecting the 
production and usage of gastrointestinal hormones that control hunger and satiety, as 
well as the composition of the gut microbiome (Cӑtoi et al., 2019). 
Crosstalk Between Obesity, Bariatric Surgery, and Depression  
Given the prevalence of coexisting obesity and depression discussed earlier, 
many patients seeking esthetically enhancing surgery, bariatric or others such as 
liposuction, show moderate to severe symptoms of depressive disorders and body image 
dysmorphia (Brito et al., 2016).  Every bariatric surgery candidate must undergo 
extensive psychological evaluations before bariatric surgery.  It is required that bariatric 
surgery patients be given increased access to resources like support groups, mentor 
programs, and nutritional support post-surgery in an attempt to lessen pre-existing 
and/or prevent the worsening of depressive symptoms during the period of rapid change 
following bariatric surgery.  However, these interventions cannot always be utilized or 
maintained by the patient, and body image dissatisfaction often increases after surgery 
as the rapid surgically induced weight loss can cause patients to seek unrealistic body 




bariatric surgery results in improved long-term depressive symptoms when measured 
two years after surgery (Gill et al., 2019).  However, other studies provide evidence of 
immediate decreases in depression levels following bariatric surgery, but these are not 
maintained as in the years following surgery symptoms of decreased mood and body 
dissatisfaction increase once again (Canetti et al., 2016).  When following a group of 
adolescence that underwent bariatric surgery over a span of five years, Järvholm et al. 
(2020) found that, while self-esteem and binge eating were improved, general mood did 
not.  Despite substantially greater weight loss compared to control, patients often report 
the same or worse overall mood, which then also positively correlates with decreased 
weight loss and/or increased weight regain following surgery (Monpellier et al., 2018). 
As part of the surgical process, patients are expected to attend follow up 
appointments for both physical and psychological care, but long-term attendance at 
these appointments is not reliable due to financial requirements, time availability, and 
geographic location limitations (Bradley et al., 2018).  Remote care has been on the rise 
and is proving beneficial thus far, particularly in the time of the Covid-19 pandemic and 
may be a useful tool to fight attendance issues in the long-term future (Rubino et al., 
2020).  Literature emphasizes the need for active intervention that targets mental health 
via life coaching to prolong weight loss, but the problem of patient attendance has yet to 
be solved (Belligoli et al., 2020; Rudolph & Hilbert, 2013). 
Cognitive Behavioral Therapy (CBT) has been associated with improved eating 
patterns, psychological symptoms, and decreased weight regain.  The current question 
being asked about CBT is when it should begin.  Some suggest that participation before 




alone does not result in any significant benefits.  When postoperative benefits of a 
normal treatment group are compared to that of a group that received CBT emphasizing 
nutritional and activity management, cognitive restructuring, and relapse prevention, 
there was no significant improvement in long-term eating behavior or depression post-
surgery (Paul et al., 2020).  However, CBT taking place briefly before and for at least 
three months following surgery, before any weight regain or problematic eating 
behaviors develop, positively correlates with improved postoperative psychological 
wellbeing (Beaulac & Sandre, 2015; David et al., 2020).   
Maintenance of pharmacotherapy for comorbidities such as hypertension and 
diabetes following bariatric surgery is vital to survival, and psychological findings 
suggest that pharmacotherapy regarding antidepressants should be no different (Bland et 
al., 2016).  With the high prevalence of psychiatric disorders in those who seek out 
bariatric surgery, approximately 35% of patients already take antidepressants before 
surgery (Hawkins et al., 2020).  The rate of antidepressant drug discontinuation is 
significantly lower than that of drugs that treat physical symptoms like hypertension, 
indicating a need for further research on how bariatric surgery affects the effectiveness 
of antidepressants (Kennedy et al., 2014).  Antidepressant medications normally come 
in the form of selective serotonin reuptake inhibitors SSRIs or selective serotonin-
norepinephrine reuptake inhibitors (SNRIs).  Patients taking SNRIs rather than SSRIs 
one year after surgery have a statistically higher percent total weight loss (Hawkins et 
al., 2020).  Sources of tryptophan can deplete when an enzyme involved in immune 
activation is overactivated.  This overactivation via chronic inflammation in obese 




individuals and persist even after surgical weight loss (Brandacher et al., 2006).  The 
decreased amount of serotonin available likely contributes to depressive symptoms after 
bariatric surgery and SSRI/SNRI drugs may not be enough to efficiently correct the 
concentration of serotonin. 
Serotonin type 2C receptor signaling is essential for weight loss, but it has been 
shown that this receptor’s signaling is not what causes post-surgical weight loss.  It may 
be possible that serotonergic drug activation of these receptors could cause weight loss 
therapeutically (Carmody et al., 2015).  Neuronal serotonin differs in obese individuals 
in that there is a much higher rate of serotonin binding to type 2A receptors, binding of 
which positively correlates with weight regulation (Haahr et al., 2015).  Significant 
decreases in the availability of SSRIs one month after bariatric surgery correlates with 
increased depressive symptoms that get better as drug availability, an indicator of 
serotonin levels, normalizes over time (Hamad et al., 2012).  This indicates that simply 
prescribing SSRIs to every bariatric surgery patient will not efficiently treat drooping 
serotonin levels, and therefore depressive symptoms, post-surgery.  A large amount of 
current research focuses on the pharmaceutical and behavioral aspects of treating 
depressive symptoms following bariatric surgery, but these are not the only possible 
targets.  Given the sheer alteration to the anatomy of the gastrointestinal tract in 
bariatric surgery, perhaps there are alterations in how the gut and the brain are 
communicating. 
The Gut-Brain Axis 
The collection of enterochromaffin cells that line the gut, the largest endocrine 




20 known hormones that play a major role in bodily homeostasis (Martin et al., 
2019).  These hormones interact with the enteric nervous system which propagates 
signals to the brain for processing.  After processing, the brain responds with signals to 
the gut as needed.  But these enterochromaffin cells function at the hand of the 
supporting gut microbiome (GM), the highly diverse and variable collection of bacteria 
(mostly anaerobes), fungi, viruses, and protozoa that reside in the intestines.  The GM 
differs slightly in each person and has been found to regulate vital physiological and 
neurological processes vital for homeostasis.  The GM greatly influences hormone 
production, and therefore neurological response. The circular communication between 
the GM and central nervous system, deemed the gut-brain axis, often occurs via the 
vagus nerve, immune system, and the enteric nervous system.  Many neuronal pathways 
connecting the gastrointestinal tract to the brain travel along the vagus nerve.  Secretion 
of enteroendocrine hormones, discussed earlier, activates receptors of afferent 
pathways, sending various signals to the brain for processing.  Each hormone, receptor, 
and neural pathway will bring about a specific response, such as changing appetite 
and/or energy expenditure to maintain homeostasis (Lyte & Cryan, 2014). 
The makeup of the GM in lean, healthy individuals has been extensively studied 
for use as a baseline when analyzing changes to the GM in any specific circumstance.  
The compositions are more broadly categorized into main phyla, and further analysis 
can determine species presence and concentration.  The main phyla that make up the 
GM are Firmicutes (genera such as Clostridium, Ruminococcus, Lactobacillus, and 
Faecalibacterium), Bacteroidetes (genera such as Bacteroides, Porphyromonas, and 




Actinobacteria (mainly Bifidobacterium), and less of the phyla Verrucomicrobiota 
(species Akkermansia muciniphila in particular).  Fungi and archaea compose less than 
1% of the GM (Ruan et al., 2020).  It is also important to note that the composition of 
the GM varies by location (Figure 3).  Utilizing location-specific populations of 





Figure 3:  Gut Microbiome Composition based on Location 
The composition of microbes in the gastrointestinal tract varies depending on location.   
Dominant genera of bacteria in the oral cavity, esophagus, stomach, small intestine, and 
colon are depicted (Ruan et al., 2020). 
Dysbiosis of the Gut Microbiome 
When an individual possesses a healthy GM, there is a symbiotic (i.e., mutually 
beneficial) relationship between the GM and the host.  For example, mice models have 
demonstrated that a healthy GM plays a vital role in the development of the central 
nervous system.  With dysbiosis of the GM, there is an imbalance of microorganisms 
that can result in an innumerable number of symptoms.  The GM actively 




nervous system, and neuroactive compounds.  For example, some bacteria in the GM 
can produce neurotransmitters, such as serotonin and dopamine, which are capable of 
activating pathways associated with the gut-brain axis (Foster & McVey Neufeld, 2013; 
Strandwitz, 2018).   Changing the GM in turn alters the signaling to and from the brain.  
Dysbiosis of the GM has been linked to many diseases, many of which are 
neuropsychological, such as irritable bowel disease, cardiovascular disease, 
Alzheimer’s disease, Parkinson’s disease, schizophrenia, as well as obesity, depression, 
or even daily stress (Barko et al., 2018).  When the microbiota of depressed patients is 
transferred to a microbiota-deficient (i.e., germ free) rat, the transplanted rat begins to 
show behavioral and psychological features that are associated with depression, 
indicating a causal role for the GM in the gut-brain axis (Kelly et al., 2016).  Similarly, 
transplantation of microbiota from obese to germ free mice results in a significantly 
larger increase in adiposity than when transplanted with microbiota from lean mice 
(Turnbaugh et al., 2008).  Transplantation of obese gut microbiota into germ free mice 
also induced neurobehavioral disruptions even in the absence of increased adiposity, 
further indicating that the GM plays a role in neurological functioning (Bruce-Keller et 
al., 2015).  As the importance of the GM in regulating brain function comes to light, 
researchers are investigating the physiological basis for the GM’s modulation of 
neurological function (Cryan et al., 2019).   
Changing a subject’s diet is the primary method of altering the GM.  Dietary 
changes have been shown to cause large adjustments to microbial concentration within 
a 24-hour period, but these changes are temporary if the healthy GM promoting diet is 




high fat diet correlates with decreased GM diversity, while increasing animal protein 
intake helps increase microbial diversity (Singh et al., 2017).  The recent development 
of microbiota transfer therapy is being used as a method to alter the GM of patients with 
conditions such as autism spectrum disorders, which often presents with gastrointestinal 
symptoms as symptom severity increases.  In an extended clinical trial using microbiota 
transfer therapy, symptoms of constipation, diarrhea, indigestion, abdominal pain, and 
behavioral symptoms of autism spectrum disorders all improved eight weeks after the 
completion of microbiota transfer therapy.  Increases in Bifidobacterium, Prevotella, 
and Desulfovibrio were noted as the main changes to GM composition (Kang et al., 
2017).  Continuing to develop the understanding of functions modulated by the GM for 
the treatment of disorders is a promising field of study. 
The Obese Microbiome 
Human studies demonstrate that obese individuals present with a decreasingly 
diverse community of microbes in the GM.  Specifically, obese individuals have a 
higher Firmicute to Bacteroidetes ratio and functional disturbances to metabolic 
pathways affected by the GM (Cӑtoi et al., 2019).  Bacteria involved in weight gain are 
thought to induce increases in the expression of genes involved with carbohydrate and 
lipid metabolism, resulting in greater energy absorption from dietary foods.  As obesity 
is already associated with greater energy intake than energy expenditure, increased 
absorption due to the GM only further complicates the development and treatment of 
obesity (John & Mullin, 2016).  Short chain fatty acids produced by the GM can 
become concentrated enough to harm lipid metabolism, possibly contributing to the 




of proteins involved in essential and nonessential amino acid metabolic pathways are 
significantly reduced in obese individuals (Sanmiguel et al., 2015).  One major aim of 
bariatric surgery is to restore metabolic functions in obese individuals, and some may 
argue that improving one’s state of mind is a secondary goal as it is a major component 
of overall health.  The mechanisms by which GM bacteria regulate metabolic and neural 





Using the PubMed database, a systematic review of the literature regarding how 
bariatric surgery and depression individually change the profile of the GM will be 
formed.  Further, studies that evaluate the gut microbiota in individuals who undergo 
bariatric surgery and individuals with depression will be analyzed in search of precise 
changes in composition corresponding to each condition (phyla, genus, etc.).  The 
relative trends in taxa were then compared to one another in search of common 
directional changes in GM abundance.  Common shifts in GM composition may 
indicate mechanisms/pathways that contribute to the continued presence of depressive 
symptoms after bariatric surgery. 
The selected term(s) for GM changes caused by bariatric surgery were “bariatric 
surgery” AND “gut microbiome.”  For analyzing GM changes with depression, the 
terms “bariatric surgery” AND “depression,” and “gut microbiome dysbiosis” AND 
“depression” were used. All searches were filtered to require a publication date on or 
after January 1, 2015.  All articles were screened based on title and abstract.  





For GM alteration caused by bariatric surgery, 3606 articles were retrieved and 
41 were selected for further analysis based on title.  For GM alteration influenced by 
depression, 930 articles were retrieved and 32 were selected for further review based on 
title.  Article abstracts were the evaluated in search of reporting species-specific 
changes in the GM.  Nine studies researching the GM after bariatric surgery and eight 
studies researching the GM in depression (17 total) were selected for demographic and 
GM content analysis.  Study demographics are described in Tables 2 and 3 and include 
citation, study description, participant number (n), population descriptions, and 
findings/outcomes.  Tables 4 and 5 reports changes in GM population expression for 
bariatric surgery and depression, respectively.  Table 6 identifies similarities in GM 
changes associated with both bariatric surgery and depression. 
In general, the analysis revealed that both post-bariatric surgery and depressed 
GMs showed an increased relative abundance of Streptococcus, Proteobacteria, 
Citrobacter, Enterobacter, Klebsiella pneumoniae, Bacteroidetes, Alistipes, 
Fusobacteria, Akkermansia, and Actinobacteria, and decreased levels of Firmicutes, 
Lactobacillus, Faecalbacterium, Ruminococcus, and Bifidobacterium.  Trends in 
Anaerostipes, Clostridium, Blautia, Veillonella, Roseburia, Escherichia, Escherichia 
coli, Bacteroides, Prevotella, and Verrucomicrobiota were divergent.  Table 7 indicates 






Table 2:  Selected Studies that Report Changes to the Gut Microbiome After Bariatric 
Surgery 
General demographics and findings of selected studies that examine changes in the GM 
after bariatric surgery.  Abbreviations are SR (systematic review), P (pilot study), and 
PC (prospective cohort study). 
Author and Publication Year Study Design Sample Population (n) Topic(s) Examined Main Findings
Cook et al., 2020 SR n=20 human studies           
n=21 invertebrate studies




controls.  Probiotic 
usage, psychological 
states and behaviors.
Could not determine a direct linkage to 
psychological conditions due to insufficient data 
in the context of bariatric surgery, increases in 
Proteobacteria and the Akkermansia  species 
of the Verrucomicrobiota phylum follow 
bariatric surgery.
Davies et al., 2019 SR
n=14 clinical studies          
n=222 participants
Metabolic benefits of 
BS
Diet, medication, and Type 2 Diabetes are 
discussed in the context of bariatric surgery and 
future research.  Bariatric surgery results in 
increased micriobial diversity in the gut.
Guo et al., 2018 SR
12 human studies, 9 animal 
studies
Metabolic benefits of 
BS
Increases of four main phyla (Bacteroidetes, 
Fusobacteria, Verrucomicriobiota, and 
Proteobacteria) follow baraitric surgery, 
mentioning of specific species follows.  More 
research is needed to determine causal and 
mechanistic metabolic affects caused by 
changing GM in bariatric surgery patients.
Lee et al., 2019 P
n=4 medical weight loss n=4 
adjustable gastric band n=4 
RYGB
GM changes in bariatric 
surgery vs. medical 
weight loss patients
Bariatric surgery increases GM diversity more 
than medical weight loss.  More research is 
needed to determine how different GM changes 
affects remission of Type 2 Diabetes.
Luijten et al., 2019 SR n=21 studies
GM changes in 
association with 
improving comorbidities 
that follow bariatric 
surgery
Changes in GM composition positively correlate 
with weight loss and Type 2 Diabetes remission, 
but an exact causal relationship has yet to be 
determined.
Mabey et al., 2020 PC n=16 bariatric surgery     
n=19 medical weight loss
GM composition after a 
decade in patients that 
had bariatric surgery 
compared to obese 
individuals that did not 
have surgery.
Long term differences in GM composition were 
reported for the surgical group, but not for the 
control group.  Subjects that underwent surgery 
had increased amounts of the families 
Verrucomicrobiaceae and Streptococcaceae, 
but decreased levels of the Bacteroidaceae 
family 10.6 years after surgery compared to the 
non-surgical group.  Increased in the 
Akkermansia  species may be linked to Type 2 
Diabetes remission.
Magouliotis et al., 2017 SR n=22 studies
Metabolic functioning 
and microbe contents 
following bariatric 
surgery
Postoperative GM compisition is more similar to 
lean and less obese patients.  Decreased 
branched chain amino acids (BCAA's) along 
with increased GLP-1 and PYY were observed 
after surgery.
Pajecki et al., 2019 PC n=9 RYGB subjects
Post surgical GM 
composition compared 
to before surgery.
Higher levels of Firmicutes and decreased levels 
Bacteroidetes after surgery were associated 
with less weight loss.  A general decrease in 
Proteobacteria was observed.
Steinert et al., 2020 P n=16 RYGB                       
n=9 control
Bacterial and fungal 
GM composition before 
and 3 months post 
bariatric surgery 
compared to healthy 
controls.
Bacterial GM diveristy significantly increased 
after surgery, but was still significantly different 
from healthy controls.  Changes in fungal 
microbiota were significant before and after 





Table 3:  Selected Articles that Report the Altered Gut Microbiome in Depressed Individuals 
General demographics and findings of selected studies that examine changes in the GM 
relating to depression.  Abbreviations are SR (systematic review), R (review), and PC 
(prospective cohort study). 
 
Author and Publication Year Study Design Sample Population (n) Topic(s) Examined Main Findings
Aizawa et al., 2016 PC n=43 depressed                      
n=57 control
Association between 
Bifidobacterium  and 
Lactobacillus  in the gut 
of patients with MDD 
compared to control.
Significantly lower Bifidobacterium  and 
trending lower Lactobacillus  counts were 
observed in MDD patients.  Consumption 
of fermented milk was associated with 
higher Bifidobacterium  counts.
Cheung et al., 2019 SR n=6 case-control studies
Relationship between GM 
composition and MDD 
compared to contols.
No clear outline of GM changes in MDD 
patients was determined.  Reports genera 
of microbiota that increased, decreased, or 
were divergent with MDD.
Du et al., 2020 R N/A
Methods by which the 
GM alters the HPA axis 
and induces depressive 
symptoms.
Alterations to the HPA axis by the GM can 
decrease levels of brain-derived 
neurotropic factor (BDNF), leading to 
depression.  Much more research is needed 
to determine causative mechanisms of the 
GM relating to depression.
Heym et al., 2019 PC n=40 subjects
Comparing GM 
composition of faecal 
samples to depression via 
self-report questionnaires
Increased Lactobaccilus  content positively 
correlated with positive self judgement, but 
further research is needed to determine the 
role of Lactobacillus  in depression.
Jiang et al., 2015 PC n=46 depressed                      
n=30 control
Comparing GM 
composition in patients 
with active and recovered 
MDD to controls.
Active MDD patients had increased 
bacterial diversity compared to healthy 
controls.  Active MDD was associated with 
increased Proteobacteria, Actinobacteria, 
and Bacteroides but decreased Firmucutes.  
Higher Faecilibacterium  levels positively 
correlated with severity of MDD 
symptoms.  Temporal and causal 
relationships still need to be determined in 
further studies.
Naseribafrouei et al., 2014 PC
n=37 depressed                      
n=18 control
GM composition of 
depressed compared to 
healthy controls
Significant differences in GM were seen at 
the order taxonomic level.  The Alistipes 
species significantly related to depression 
severity.
Macedo et al., 2017 SR n=120 studies
GM associated with 
depression and treating an 
altered GM with SSRIs 
and antimicrobials
Depression associated GM phenotype 
reported.  Explains the possible 
neuroprotective effects of antidepressants 
and antimicrobials which may act by altering 
GM composition.
Slyepchenko et al., 2017 R N/A
Relationship between GM 
and diet on the 
pathophsyiology of MDD
Dysbiosis of the GM and a leaky gut my 
greatly influence MDD via immune 
activation and neuroplasticity.  More 
research is needed to determine exact 






Table 4:  Trends in Gut Microbiome Dysbiosis Associated with Bariatric Surgery 
Trend data extracted from selected articles relating bariatric surgery to changes in the 
gut microbiome.  Microbiota are categorized by phyla, with genus or species listed 
below belonging to the above phylum.  Trends were increase (↑, pink), decrease (↓, 
blue), or reports of increased and decreased prevalence (↑/↓, yellow), or not reported 































































































Firmicutes Phylum ↓ ↓ ↓ ↓ ↓ NR ↑/↓ ↑/↓ ↓
Anaerostipes Genus NR ↓ ↓ NR NR NR ↓ NR NR
Lactobacillus Genus NR ↓ NR NR ↓ NR ↓ ↓ NR
Clostridium Genus NR NR ↓ NR ↑/↓ NR ↓ ↓ NR
Blautia Genus NR NR ↓ NR NR NR ↓ NR ↓
Faecalibacterium Genus NR ↓ ↓ ↑ NR NR ↓ NR ↓
Streptococcus Genus NR NR NR ↑ ↑ ↑ ↑ NR ↑
Ruminococcus Genus NR NR ↓ NR NR NR ↓ NR NR
Veillonella Genus NR NR ↑ ↑ ↑ NR ↑ NR NR
Roseburia Genus NR ↓ NR ↓ ↑ NR ↓ NR ↓
Proteobacteria Phylum ↑ ↑ ↑ ↑ ↑ NR ↑ ↓ ↑
Citrobacter Genus NR NR ↑ ↑ NR NR ↑ NR NR
Enterobacter Genus NR NR ↑ ↑ ↑ NR ↑ NR NR
Escherichia Genus ↑ ↑ ↑ NR ↑/↓ NR ↑ NR ↑
Eschericha coli Species ↑ ↑ ↑ ↑ ↑ NR ↑ NR ↑
Klebsiella pneumoniae Species NR ↑ ↑ NR ↑ NR ↑ NR ↑
Bacteroidetes Phylum ↑/↓ ↑ ↑ ↑/↓ ↑/↓ ↑/↓ ↑ ↑/↓ ↑/↓
Parabacteroides Genus NR NR ↑ NR NR NR NR NR NR
Bacteroides Genus NR NR NR NR ↑ NR ↑ ↑/↓ NR
Prevotella Genus NR NR NR NR ↑ NR ↑ NR ↑/↓
Alistipes Genus NR NR ↑ NR NR NR ↑ NR NR
Fusobacteria Phylum NR NR ↑ ↑ ↑ NR NR NR NR
Verrucomicrobiota Phylum ↑/↓ NR ↑ ↑ NR ↑ NR NR ↑/↓
Akkermansia Genus ↑ ↑ ↑ ↑ ↑ ↑ ↑ NR NR
Actinobacteria Phylum ↑/↓ ↓ NR ↑ ↑ NR ↑ NR ↓





Table 5:  Trends in Gut Microbiome Dysbiosis Associated with Depression 
Trend data extracted from selected articles relating the gut microbiome to depression.  
Microbiota are categorized by phyla, with genus or species listed below belonging to 
the above phylum.  Trends were increase (↑, pink), decrease (↓, blue), or reports of 





























































































Firmicutes Phylum NR ↑/↓ ↓ NR ↓ ↑ ↓ ↑
Anaerostipes Genus NR ↑ NR NR NR NR NR NR
Lactobacillus Genus ↓ ↓ ↓ ↓ NR NR NR ↓
Clostridium Genus NR ↑ NR NR ↑ NR ↑ ↑
Blautia Genus NR ↑ NR NR ↑ NR NR NR
Faecalibacterium Genus NR ↓ ↓ NR ↓ NR ↓ ↓
Streptococcus Genus NR ↑ NR NR NR NR NR NR
Ruminococcus Genus NR ↓ ↓ NR ↓ NR NR ↑
Veillonella Genus NR NR NR NR NR NR NR NR
Roseburia Genus NR ↑/↓ NR NR ↑ NR NR NR
Proteobacteria Phylum NR ↑/↓ ↑ NR ↑ NR ↑ NR
Citrobacter Genus NR NR NR NR NR NR ↑ ↑
Enterobacter Genus NR NR NR NR ↑ NR ↑ NR
Escherchia Genus NR ↓ NR NR NR NR NR NR
Escherchia coli Species NR ↓ NR NR NR NR ↑ NR
Klebsiella pneumoniae Species NR ↑ NR NR NR NR ↑ ↑
Bacteroidetes Phylum NR ↑/↓ ↑ NR ↓ ↑ ↑ ↑
Parabacteroides Genus NR ↑ NR NR ↑ NR NR ↑
Bacteroides Genus NR ↑/↓ NR NR ↓ ↑ NR NR
Prevotella Genus NR ↑/↓ NR NR ↓ NR NR NR
Alistipes Genus NR ↑/↓ ↑ NR ↑ ↑ ↑ ↑
Fusobacteria Phylum NR ↑/↓ NR NR ↑ NR NR NR
Verrucomicrobiota Phylum NR NR NR NR NR NR NR NR
Akkermansia Genus NR ↑ NR NR NR NR NR NR
Actinobacteria Phylum NR ↑ ↑ NR ↓ NR ↑ ↑





Table 6:  Overall Trends in Gut Microbiome Dysbiosis from Tables 4 and 5 
Overall trends of each microbiota for changes associated with bariatric surgery and 
depression.  The * symbol represents similar trends, indicating a positive correlation 
between bariatric surgery and depressive GM phenotypes.  Trends were increase (↑, 




























Firmicutes* Phylum ↓ ↓
Anaerostipes Genus ↓ ↑
Lactobacillus* Genus ↓ ↓
Clostridium Genus ↓ ↑
Blautia Genus ↓ ↑
Faecalibacterium* Genus ↓ ↓
Streptococcus * Genus ↑ ↑
Ruminococcus* Genus ↓ ↓
Veillonella Genus ↑ CD
Roseburia Genus ↓ ↑
Proteobacteria* Phylum ↑ ↑
Citrobacter* Genus ↑ ↑
Enterobacter* Genus ↑ ↑
Escherichia Genus ↑ ↓
Eschericha coli Species ↑ CD
Klebsiella pneumoniae* Species ↑ ↑
Bacteroidetes* Phylum ↑ ↑
Parabacteroides* Genus ↑ ↑
Bacteroides Genus ↑ CD
Prevotella Genus ↑ CD
Alistipes* Genus ↑ ↑
Fusobacteria* Phylum ↑ ↑
Verrucomicrobiota Phylum ↑ CD
Akkermansia* Genus ↑ ↑
Actinobacteria* Phylum ↑ ↑





Table 7:  Location of Bacteria with Similar Trends of Abundance in the Gut 
Microbiome of Depressed and Bariatric Surgery Patients 
Known locations of bacteria along the gastrointestinal tract for identified bacterial taxa 
that mutually change in depressed and bariatric surgery gut microbiomes (Ruan et al., 
2020; Shigwedha & Ji, 2013) 





























Ruminococcus     
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Although bariatric surgery has generally been shown to alter microbial diversity 
in the GM, the surgery does not restore a lean/control GM and beneficial changes may 
begin digressing as soon as six months after surgery (Shen et al., 2019).  GM 
composition is often still compared to lean/healthy individuals so that relative changes 
can be compared between patient/intervention and control groups.  By comparing 
changes in the GM in depressed and bariatric surgery populations to that of lean 
individuals, similar trends indicate similar markers of GM dysbiosis.  Some studies 
indicate that the changes to the GM caused by both surgical and medical/dietary weight 
loss may be harmful.  In medical weight loss, the nutrient absorbing abilities of the GM 
increase, making it difficult for people to continue losing weight in this manner 
(Damms-Machado et al., 2015).  Even though surgical intervention has been shown to 
increase the abundance of some beneficial bacteria, such as Faecalibacterium, these 
changes are not large enough to restore a lean phenotype.  There are also some 
alterations in potentially harmful bacterial populations following bariatric surgery, such 
as the phyla Proteobacteria which impacts intestinal absorption and pH, possibly 
resulting in long-term detriments in colonic function, preventing weight loss and 
contributing to neurobehavioral deficits (Seganfredo et al., 2017).  The lack of lean GM 
restoration indicates the need for other treatment targets, such as plant fibers that feed 
beneficial bacteria known as prebiotics, which aim to restore the composition of a lean 
GM phenotype in obese and depressed individuals. 
Other than diet, a common method used to alter GM composition is probiotic 




probiotics together could increase the efficacy of lean GM restoration (Damms-
Machado et al., 2015).  Studies looking into how administration of microbe specific 
probiotics may be able to alleviate a variety of symptoms is actively underway, 
particularly for the use of bacteria belonging to the Lactobacillus and Bifidobacterium 
genera.  The species tested to treat depressive symptoms are often the same as those that 
have obesity fighting affects (Dinan et al., 2013).  Administration of Bifidobacterium 
longum and Lactobacillus helveticus, both from genuera that decrease in both bariatric 
surgery and depressed GM phenotypes, has been shown to improve symptoms of 
depression and decrease levels of cortisol by inhibiting activation of the hypothalamic-
pituitary-adrenal axis, important for immune activation, stress response, digestion, and 
mood (Ait-Belgnaoui et al., 2014; Messaoudi et al., 2011).  Alterations in pro-
inflammatory cytokine release have been restored to normal along with the resolution of 
separation-induced depressive behavior by administering Bifidobacterium infantis 
(Desbonnet et al., 2010).  Treatment with Bifidobacterium infantis is also correlated 
with greater levels of peripheral tryptophan available for serotonin synthesis, perhaps 
leading to increased neural serotonin production and improved mood (O’Mahony et al., 
2015).  The effect caused by the probiotic depends on its specific formula of bacterial 
taxa, and the roles of many species have yet to be determined. 
Some species within the GM have been found to produce precursors to 
neurotransmitters, such as tryptophan, or even some neurotransmitters themselves 
including serotonin, dopamine, and gamma (γ) aminobutyric acid (GABA), all of which 
are associated with the neurochemical aspects of depression.  Both Lactobacillus brevis 




neurotransmitter of the central nervous system, and probiotic supplementation with 
several species from the Bifidobacterium genus have been seen to produce elevated 
levels of dopamine and serotonin (Du et al., 2020).  A higher abundance of Alistipes, a 
bacterium capable of utilizing tryptophan, may also decrease serotonin production by 
limiting tryptophan availability (Slyepchenko et al., 2017).  Many studies are focusing 
on how the GM modulates production of brain derived neurotrophic factor, a factor 
involved in neuroplasticity that is often reduced in patients with depression and/or 
obesity (Naseribafrouei et al., 2014).  High fat diet induced dysbiosis of the GM in mice 
results in decreased levels of brain derived neurotrophic factor and reduced cognitive 
ability, indicating a role for the GM in the regulation of neuroplasticity and mood 
symptoms via regulation of brain derived neurotrophic factor levels (Schachter et al., 
2018).   
Obesity is associated with chronic, low-grade inflammation in peripheral tissues, 
first examined when the pro-inflammatory cytokine known as tumor necrosis-factor 
alpha (TNF-α) was found to be significantly elevated in the blood and adipose tissue of 
obese individuals (Hotamisligil et al., 1995).  Obesity related inflammation is often 
linked to metabolic syndrome, the coexistence of hypertension, hyperglycemia, altered 
cholesterol (dyslipidemia), and visceral fat accumulation which together increases one’s 
risk for cardiovascular disease, diabetes, and stroke (Alberti et al., 2005).  Adipose 
tissue possesses immune cells that secrete inflammatory factors (cytokines, adipokines), 
and increased adiposity in obese individuals results in higher levels of circulating 
inflammatory factors which results in what is known as chronic low-grade 




recruits macrophages to adipose tissue in an inflammatory response, contributing to 
comorbidities such as insulin resistance that are associated with obesity (Ouchi et al., 
2011).   
Similarly, inflammatory response has been shown to play a cyclical and dose-
dependent role in depression.  Individuals with major depressive disorder often respond 
to stressors with a greater inflammatory response compared to controls, and increased 
inflammatory immune activation can induce depressive symptoms.  Higher levels of 
pro-inflammatory factors TNF-α, IL-6, and C-reactive protein have been found in 
depressed individuals (Kiecolt-Glaser et al., 2015).  Cytokines released during sickness 
can cross and/or disrupt the functioning of the blood brain barrier, causing inflammation 
within the central nervous system which may contribute to symptoms of depression.  
Hyperactivation of the hypothalamic-pituitary-adrenal axis by cytokines IL-6 and TNF-
α activates a cascade that induces a greater stress response via release of cortisol, the 
stress hormone also associated with conditions like obesity and anxiety, from the 
adrenal gland.  These cytokines also inhibit the homeostatic loop that tells the 
hypothalamic-pituitary-adrenal axis to slow and decrease cortisol release (Dantzer et al., 
2008).  Cytokines have also been found responsible for increasing the activity of the 
enzyme that converts the amino acid tryptophan into kynurenine, decreasing available 
tryptophan molecules and slowing serotonin production.  In addition, IL-6 and TNF-α 
are associated with the increased breakdown of serotonin molecules, further depleting 
serotonin levels necessary for mood regulation (Rosenblat et al., 2014). 
The mechanisms by which the microbiota in the gut contribute to inflammatory 




microbiota to inflammatory diseases.  For example, decreases in the phyla Firmicutes 
and increases in the phyla Proteobacteria, essential for regulating intestinal absorption, 
pH, and digestion speed, have been documented in patients with irritable bowel disease, 
of which 49% also have depression, characterized by chronic inflammation of the 
gastrointestinal tract (Rosenblat et al., 2014).  Studies show that the presence of an 
inflammation-promoting GM, such as that seen in obese individuals, increases intestinal 
permeability and subsequently peripheral and central inflammation, encouraging 
neurological dysfunction (Bruce-Keller et al., 2015; Seganfredo et al., 2017).  
Depressed and obese subjects have been seen to have a decreased abundance of anti-
inflammatory Faecalibacterium along with an increased abundance of pro-
inflammatory Alistipes (Du et al., 2020).  One possible mechanism for an increased 
inflammatory response comes from the GM’s production of lipopolysaccharides which 
activate TNF-α synthesis and increase gut permeability.  When injected with 
lipopolysaccharides, human subjects had higher levels of cytokines in the blood and 
demonstrated increased anxiety and negative mood (Cani et al., 2008; Grigoleit et al., 
2011).  Increased gut permeability may allow for greater translocation of pathogenic 
bacteria across the intestinal membrane, further contributing to levels of inflammation.   
Altered GM states may also alter the ability of bacteria to produce short chain 
fatty acids (SCFAs) in the gut.  However, the mechanisms as to how SCFAs affect 
obesity and/or depression are up still up for debate.  SCFAs are produced when bacteria 
ferment dietary fibers, starches, unabsorbed sugars, and undigested proteins within the 
large intestine.  These SCFAs can be used as energy by epithelial cells and may also 




available for host use, making the host susceptible to energy substrate accumulation and 
fat deposition at higher concentrations.  Communication via the gut-brain axis also 
occurs via SCFAs which stimulate the release of anorexigenic hormones peptide YY 
and glucagon-like peptide 1 upon binding to enterochromaffin cell receptors (Cӑtoi et 
al., 2019).  Some suggest that increased SCFA production is protective against obesity 
and associated with improved host metabolism, glucose homeostasis, and energy 
balance.  For example, increased levels of the SCFA butyrate in the gut, primarily 
produced by Firmicutes, Lactobacillus, and Bifidobacterium which are all decreased in 
depressed and obese individuals after bariatric surgery, has been associated with higher 
insulin sensitivity, whereas subjects with lower levels of butyrate are at greater risk for 
Type 2 Diabetes (Sanna et al., 2019; Seganfredo et al., 2017).  It has also been 
suggested that SCFAs regulate the host’s immune response by decreasing the secretion 
of pro-inflammatory cytokines.  While the mechanism is unclear, decreased production 
of SCFAs may be a cause of chronic inflammation which may cause neural 
inflammation that impacts neurological functioning (Sun et al., 2017).  The mechanisms 
by which gut derived SCFAs and other bacteria within the GM impact host physiology 
and psychology are largely yet to be determined, but ongoing research proves promising 





As can be inferred from the results, changes in the GM are quite dependent on 
the individual.  While there are clearly trending similarities between the general GM 
makeup of bariatric surgery and depressed patients, recognizing relative changes in 
composition is only the beginning.  The GM can be altered by nearly anything.  
Whether it be diet, surgery, stress levels, medication, etc., variances in GM composition 
are expected whether they are permanent or not.  This makes studying dysbiosis of the 
GM difficult and indicates a requirement for the determination of exact species-host 
response mechanisms for successful personalized treatment via the GM.  Ongoing 
research aims to determine said mechanisms that relate specific phyla and species to 
host physiology in accordance with all types of physiological and psychological 
conditions, and much more research must be performed to determine how a seemingly 
infinite number of systems are homeostatically regulated according to the state of the 
GM. 
As demonstrated, the interplay between the gut and the brain is extremely 
complex and depends on a wide variety of factors.  As the search for which species play 
a role in modulating host response, it is important that the mechanism of action by 
which a species induces said affect is also examined.  Dysbiosis of the GM is associated 
with many conditions and regulating the composition of the GM has become a very 
popular method of treating physical and psychological symptoms.  Ongoing symptoms 
of depression following bariatric surgery may be associated with a lingering pro-
inflammatory GM phenotype capable of inducing neurobehavioral deficits via a variety 




immune response.  Fecal sample analysis and transplantation will continue to play a key 
role in determining both the correlation and causation between the GM and host 
physiology as the taxonomical characterization of GM dysbiosis according to 
diagnosable conditions could prove an invaluable tool for personalizing treatments for 
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